About AMRN

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes commitment to an ongoing outcomes study. Amarin's first product, Vascepa (icosapent ethyl) capsules, is a highly pure EPA omega-3 prescription product.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

AMRN is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
BIB ProShares Ultra Nasdaq Biotechnology 212.2 M 2.1215E+08 234 234 0.33% 0.00334999 1.6 M 1558840
UBIO Proshares UltraPro Nasdaq Biotechnology 28.4 M 2.839E+07 227 227 0.21% 0.00214924 199 K 199143
ADRD Invesco BLDRS Developed Markets 100 ADR Index Fund 33.4 M 3.34E+07 82 82 0.16% 0.00157 52 K 52423
ADRU Invesco BLDRS Europe Select ADR Index Fund 11.6 M 1.16E+07 69 69 0.19% 0.00191 22 K 22214
IBB iShares Nasdaq Biotechnology Index Fund 7.3 B 7.33983E+09 221 221 0.82% 0.0082 60.3 M 6.0299E+07
ONEQ Fidelity Nasdaq Composite Index Tracking Stock 2.1 B 2.1E+09 1,002 1002 0.04% 0.000438295 921 K 921258